The FDA Recommends Authorizing the Pfizer Vaccine for Young Children

A key Food and Drug Administration (FDA) expert advisory panel on Tuesday recommended the agency authorize Pfizer’s COVID-19 vaccine for use in children between the ages of 5 and 11, bringing those children one step closer to getting a shot.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) found that the benefits of the vaccine outweighed its risks and voted nearly unanimously 17-0, with one abstention, to recommend the agency authorize the shot.

FDA is not bound to follow the panel’s recommendation, though it often does. 

Read the source article at The Hill

    Leave a Review or Comment

    Your email address will not be published. Required fields are marked *

    Back to top button